$MHTX
MANHATTAN SCIENTIFICS INC

2022 Q3 Form 10-Q Financial Statement

#000147793222006093 Filed on August 15, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $9.000K $41.00K $0.00
YoY Change -18.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $175.0K $193.0K $180.0K
YoY Change 0.0% -7.66% -0.55%
% of Gross Profit
Research & Development $2.000K $2.000K $3.000K
YoY Change -33.33% 0.0% 0.0%
% of Gross Profit
Depreciation & Amortization $0.00 $1.000K $1.000K
YoY Change -100.0% -66.67% 0.0%
% of Gross Profit
Operating Expenses $2.000K $2.000K $3.000K
YoY Change -33.33% 0.0% 0.0%
Operating Profit -$168.0K -$154.0K -$183.0K
YoY Change -5.62% -4.35% -0.54%
Interest Expense $7.000K $6.000K -$464.0K
YoY Change 0.0% -14.29% -7833.33%
% of Operating Profit
Other Income/Expense, Net $97.00K -$1.462M -$464.0K
YoY Change -109.92% -39.64% -245.91%
Pretax Income -$71.00K -$1.616M -$647.0K
YoY Change -93.86% -37.44% -582.84%
Income Tax
% Of Pretax Income
Net Earnings -$71.00K -$1.616M -$647.0K
YoY Change -93.86% -37.44% -582.84%
Net Earnings / Revenue -788.89% -3941.46%
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 559.3M shares 559.3M shares 559.3M shares
Diluted Shares Outstanding 559.3M shares 559.3M shares 559.3M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $288.0K $386.0K $121.0K
YoY Change -21.31% -14.6% -52.36%
Cash & Equivalents $288.0K $386.0K $121.0K
Short-Term Investments
Other Short-Term Assets $8.000K $14.00K $19.00K
YoY Change 14.29% 16.67% 11.76%
Inventory
Prepaid Expenses $8.000K $14.00K $19.00K
Receivables
Other Receivables
Total Short-Term Assets $296.0K $400.0K $440.0K
YoY Change -56.02% -47.64% -22.94%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $2.000K $3.000K
YoY Change -60.0% -60.0% -62.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.064M $960.0K $2.444M
YoY Change -62.08% -74.63% -60.57%
Other Assets $2.000K $2.000K $2.000K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.068M $964.0K $2.449M
YoY Change -62.03% -74.57% -62.38%
TOTAL ASSETS
Total Short-Term Assets $296.0K $400.0K $440.0K
Total Long-Term Assets $1.068M $964.0K $2.449M
Total Assets $1.364M $1.364M $2.889M
YoY Change -60.87% -70.05% -59.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $115.0K $118.0K $107.0K
YoY Change -25.32% -27.16% -36.69%
Accrued Expenses $1.351M $1.273M $1.201M
YoY Change 24.98% 28.2% 28.45%
Deferred Revenue
YoY Change
Short-Term Debt $139.0K $143.0K $135.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.605M $1.534M $1.443M
YoY Change 29.96% 32.81% 30.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.605M $1.534M $1.443M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.605M $1.534M $1.443M
YoY Change 18.1% 20.6% 18.86%
SHAREHOLDERS EQUITY
Retained Earnings -$70.85M -$70.78M -$69.17M
YoY Change 3.46% 5.13%
Common Stock $559.0K $559.0K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.299M -$1.228M $388.0K
YoY Change
Total Liabilities & Shareholders Equity $1.364M $1.364M $2.889M
YoY Change -60.87% -70.05% -59.19%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$71.00K -$1.616M -$647.0K
YoY Change -93.86% -37.44% -582.84%
Depreciation, Depletion And Amortization $0.00 $1.000K $1.000K
YoY Change -100.0% -66.67% 0.0%
Cash From Operating Activities -$88.00K -$63.00K -$111.0K
YoY Change -1.12% -38.24% 15.63%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $328.0K
YoY Change 9.33%
Cash From Investing Activities $0.00 $328.0K $0.00
YoY Change -100.0% 9.33% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 0.000 $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -88.00K -63.00K -$111.0K
Cash From Investing Activities 0.000 328.0K $0.00
Cash From Financing Activities -10.00K 0.000 $0.00
Net Change In Cash -98.00K 265.0K -$111.0K
YoY Change 13.95% 33.84% 12.12%
FREE CASH FLOW
Cash From Operating Activities -$88.00K -$63.00K -$111.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$63.00K -$111.0K
YoY Change -38.24% 19.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
mhtx Weighted Average Exercise Price Expired
WeightedAverageExercisePriceExpired
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2021Q2 mhtx Other Income Expense
OtherIncomeExpense
0
dei Entity Central Index Key
EntityCentralIndexKey
0001099132
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
447804 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
559281064 shares
CY2021Q4 us-gaap Assets
Assets
3454000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
102000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1129000 usd
CY2022Q2 us-gaap Notes Payable
NotesPayable
143000 usd
CY2021Q4 us-gaap Notes Payable
NotesPayable
130000 usd
mhtx Other Income Expense
OtherIncomeExpense
0
mhtx Other Income Expense
OtherIncomeExpense
0
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
MANHATTAN SCIENTIFICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity File Number
EntityFileNumber
000-28411
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0460639
dei Entity Address Address Line1
EntityAddressAddressLine1
244 Fifth Ave
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2341
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10001
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
726-2107
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
559281064 shares
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15000 usd
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
300000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
547000 usd
CY2021Q4 us-gaap Investments
Investments
2901000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4000 usd
CY2021Q4 us-gaap Other Assets
OtherAssets
2000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1361000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
1361000 usd
CY2022Q2 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
1058000 usd
CY2021Q4 us-gaap Redeemable Noncontrolling Interest Equity Preferred Carrying Amount
RedeemableNoncontrollingInterestEquityPreferredCarryingAmount
1058000 usd
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
447804 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0 usd
CY2021Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
0 usd
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
559281064 shares
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3454000 usd
CY2022Q2 us-gaap Revenues
Revenues
41000 usd
CY2021Q2 us-gaap Revenues
Revenues
50000 usd
us-gaap Revenues
Revenues
41000 usd
us-gaap Revenues
Revenues
50000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
193000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
209000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
373000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
390000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5000 usd
CY2022Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
195000 usd
CY2021Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
211000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
378000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
395000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-154000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-161000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-337000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-345000 usd
CY2022Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-1456000 usd
CY2021Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-2415000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-1913000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
-2091000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
6000 usd
CY2021Q2 us-gaap Interest Expense
InterestExpense
7000 usd
us-gaap Interest Expense
InterestExpense
13000 usd
us-gaap Interest Expense
InterestExpense
13000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1462000 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2422000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1926000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2104000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1616000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2583000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2263000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2449000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1035000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
388000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1616000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
154000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
99000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
232000 usd
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
353000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
386000 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
452000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4674000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
134000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
4808000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2583000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2225000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2263000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2449000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
1913000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
2091000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
0 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
16000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
144000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
140000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-174000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-198000 usd
mhtx Purchase Of Fixed Assets
PurchaseOfFixedAssets
0 usd
mhtx Purchase Of Fixed Assets
PurchaseOfFixedAssets
-3000 usd
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
28000 usd
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0 usd
us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
300000 usd
us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
300000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
328000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
297000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Interest Paid
InterestPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70783000 usd
CY2022Q2 mhtx Working Capital
WorkingCapital
-1134000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</p>
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-1616000 usd
mhtx Cash Concentration
CashConcentration
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of June 30, 2022 and December 31, 2021, we had cash balances of $102,000 and $0 exceeding the federally insured limits.</p>
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
102000 usd
CY2021 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
0 usd
CY2022Q2 us-gaap Investments
Investments
960000 usd
CY2021Q4 us-gaap Investments
Investments
2901000 usd
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
15000 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
mhtx Aggregate Intrinsic Value Granted
AggregateIntrinsicValueGranted
0 usd
mhtx Aggregate Intrinsic Value Exercised
AggregateIntrinsicValueExercised
0 usd
CY2018 mhtx Adjusted Asset Valuation
AdjustedAssetValuation
1200000 usd
CY2019 mhtx Sale Of Asset
SaleOfAsset
1200000 usd
CY2019 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
300000 usd
CY2019Q4 mhtx Remaining Amount Of Assets
RemainingAmountOfAssets
900000 usd
CY2021 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
300000 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-2583000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
CY2021Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
mhtx Common Stock Owned Share
CommonStockOwnedShare
51766508 shares
us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
28922917 shares
us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
34922917 shares
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Profit Loss
ProfitLoss
-2263000 usd
us-gaap Profit Loss
ProfitLoss
-2449000 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
559281064 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
559281064 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.04
CY2021 mhtx Weighted Average Life Outstanding Ending Balance
WeightedAverageLifeOutstandingEndingBalance
P6Y21D
mhtx Begining Balance
BeginingBalance
2901000 usd
mhtx Change Due To The Sale Of Securities
ChangeDueToTheSaleOfSecurities
-28000 usd
mhtx Change In The Unrealized Fair Value Of Securities
ChangeInTheUnrealizedFairValueOfSecurities
-1913000 usd
mhtx Ending Balance
EndingBalance
960000 usd
CY2019Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7000 usd
mhtx Schedule Of Debt Discount
ScheduleOfDebtDiscount
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">150,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Less: Discounts on notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,000 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notes payable, net of discounts</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">143,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
150000 usd
CY2022Q2 mhtx Less Discounts On Notes Payable
LessDiscountsOnNotesPayable
-7000 usd
CY2022Q2 us-gaap Notes Payable
NotesPayable
143000 usd
mhtx Aggregate Intrinsic Value Expired
AggregateIntrinsicValueExpired
0 usd
CY2022Q2 mhtx Weighted Average Exercise Price Ending
WeightedAverageExercisePriceEnding
0.04
mhtx Weighted Average Life Outstanding Ending Balance
WeightedAverageLifeOutstandingEndingBalance
P5Y10M13D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26500000 shares
mhtx Royalty Percentage On Dental Products
RoyaltyPercentageOnDentalProducts
0.10 pure
mhtx Royalty Percentage On Other Licensed Products
RoyaltyPercentageOnOtherLicensedProducts
0.05 pure
us-gaap Royalty Expense
RoyaltyExpense
41000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1273000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1129000 usd

Files In Submission

Name View Source Status
0001477932-22-006093-index-headers.html Edgar Link pending
0001477932-22-006093-index.html Edgar Link pending
0001477932-22-006093.txt Edgar Link pending
0001477932-22-006093-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mhtx-20220630.xsd Edgar Link pending
mhtx_10q.htm Edgar Link pending
mhtx_ex311.htm Edgar Link pending
mhtx_ex321.htm Edgar Link pending
mhtx-20220630_pre.xml Edgar Link unprocessable
mhtx-20220630_cal.xml Edgar Link unprocessable
mhtx-20220630_def.xml Edgar Link unprocessable
mhtx-20220630_lab.xml Edgar Link unprocessable
mhtx_10q_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable